4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells

Free Radical Biology and Medicine

Volumn 42, Issue 11, 2007, Pages 1661-1670

  Cerbone, Angelo ^a   Toaldo, Cristina ^b   Laurora, Stefano ^b   Briatore, Federica ^b   Pizzimenti, Stefania ^b   Dianzani, Mario U ^b   Ferretti, Carlo ^b   Barrera, Giuseppina ^b  

^a Istituto di Ricerche Biomediche A Maxer RBM spa   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

15d Prostaglandin J2; 4 Hydroxynonenal; Apoptosis; CaCo 2 cells; Differentiation; Free radicals; PPAR ; Proliferation; Rosiglitazone

Indexed keywords

4 HYDROXYNONENAL; MYC PROTEIN; PROSTAGLANDIN J2; PROTEIN BAX; PROTEIN P21; ROSIGLITAZONE; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4-HYDROXY-2-NONENAL; ALDEHYDE; CROSS LINKING REAGENT; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL STRAIN CACO 2; COLON TUMOR; DRUG EFFECT; GENETICS; METABOLISM;

ALDEHYDES; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CACO-2 CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; CYSTEINE PROTEINASE INHIBITORS; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; LIGANDS; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES;

EID: 34247383583     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.02.009     Document Type: Article

References (47)

1. Lowell B.B. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
2. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
3. Gupta R.A., and Dubois R.N. Controversy: PPARgamma as a target for treatment of colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002) G266-G269
4. Sporn M.B., Suh N., and Mangelsdorf D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 7 (2001) 395-400
5. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
6. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA. 94 (1997) 4318-4323
7. Pandhare J., Cooper S.K., and Phang J.M. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. J. Biol. Chem. 281 (2006) 2044-2052
8. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Muratami A., and Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61 (2001) 2424-2428
9. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
10. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chapelle A., Spiegelman B.M., and Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol. Cell 3 (1999) 799-804
11. Borek C. Dietary antioxidants and human cancer. Integr. Cancer Ther. 3 (2004) 333-341
12. Staib F., Robles A.I., Varticovski L., Wang X.W., Zeeberg B.R., Sirotin M., Zhurkin V.B., Hofseth L.J., Hussain S.P., Weinstein J.N., Galle P.R., and Harris C.C. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 65 (2005) 10255-10264
13. Gao J., Liu X., and Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA. 102 (2005) 17207-17212
14. Vizio B., Poli G., Chiarpotto E., and Biasi F. 4-Hydroxynonenal and TGF-β1 concur in inducing antiproliferative effects on the CaCo-2 human colon adenocarcinoma cell line. BioFactors 24 (2005) 237-246
15. Dianzani M.U. 4-Hydroxynonenal from pathology to physiology. Mol. Aspects Med. 24 (2003) 263-272
16. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
17. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42 (2003) 318-343
18. Awasthi Y.C., Ansari G.A., and Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. Methods Enzymol. 401 (2005) 379-407
19. Yang Y., Sharma R., Sharma A., Awasthi S., and Awasthi Y.C. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim. Pol. 50 (2003) 319-336
20. Barrera G., Di Mauro C., Muraca R., Ferrero D., Cavalli G., Fazio V.M., Paradisi L., and Dianzani M.U. Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. Exp. Cell Res. 197 (1991) 148-152
21. Barrera G., Pizzimenti S., Muraca R., Barbiero G., Bonelli G., Baccino F.M., Fazio V.M., and Dianzani M.U. Effect of 4-hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Free Radic. Biol. Med. 20 (1996) 455-462
22. Awasthi Y.C., Sharma R., Cheng J.Z., Yang Y., Sharma A., Singhal S.S., and Awasthi S. Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. Mol. Aspects Med. 24 (2003) 219-230
23. Hara A., Hibi T., Yoshioka M., Toda K., Watanabe N., Hayashi A., Iwao Y., Saito H., Watanabe T., and Tsuchiya M. Changes in proliferative activity and phenotypes in spontaneous differentiation of a colon cancer cell line. Jpn. J. Cancer Res. 84 (1993) 625-632
24. Laurora S., Pizzimenti S., Briatore F., Fraioli A., Maggio M., Reffo P., Ferretti C., Dianzani M.U., and Barrera G. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J. Pharmacol. Exp. Ther. 305 (2003) 932-942
25. Fazio V.M., Barrera G., Martinotti S., Farace M.G., Giglioni B., Frati L., Mannari V., and Dianzani M.U. 4-Hydroxynonenal, a product of cellular lipid peroxidation, which modulates c-myc and globin gene expression in K562 erythroleukemic cells. Cancer Res. 52 (1992) 4866-4871
26. Yang F.G., Zhang Z.W., Xin D.Q., Shi C.J., Wu J.P., Guo Y.L., and Guan Y.F. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol. Sin. 26 (2005) 753-761
27. He G., Thuillier P., and Fischer S.M. Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. J. Invest. Dermatol. 123 (2004) 1110-1119
28. Pizzimenti S., Barrera G., Dianzani M.U., and Brusselbach S. Inhibition of D1, D2, and A-cyclin expression in HL-60 cells by the lipid peroxidation product 4-hydroxynonenal. Free Radic. Biol. Med. 26 (1999) 1578-1586
29. Pizzimenti S., Briatore F., Laurora S., Toaldo C., Maggio M., De Grandi M., Meaglia L., Menegatti E., Giglioni B., Dianzani M.U., and Barrera G. 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic. Biol. Med. 40 (2006) 1578-1591
30. Laurora S., Tamagno E., Briatore F., Bardini P., Pizzimenti S., Toaldo C., Reffo P., Costelli P., Dianzani M.U., Danni O., and Barrera G. 4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line. Free Radic. Biol. Med. 38 (2005) 215-225
31. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
32. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
33. Zahradka P., Wright B., Fuerst M., Yurkova N., Molnar K., and Taylor C.G. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 317 (2006) 651-659
34. Eucker J., Sterz J., Krebbel H., Zavrski I., Kaiser M., Zang C., Heider U., Jakob C., Elstner E., and Sezer O. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer Drugs 17 (2006) 763-769
35. Chen Z.Y., and Tseng C.C. 15-Deoxy-delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol. Pharmacol. 68 (2005) 1203-1213
36. Nakata S., Yoshida T., Shiraishi T., Horinaka M., Kouhara J., Wakada M., and Sakai T. 15-Deoxy-delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol. Cancer Ther. 5 (2006) 1827-1835
37. Chaffer C.L., Thomas D.M., Thompson E.W., and Williams E.D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6 (2006) 53
38. Chen Y.C., Shen S.C., and Tsai S.H. Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim. Biophys. Acta 1743 (2004) 291-304
39. Shimada T., Kojima K., Yoshiura H., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658-664
40. Bull A.W., Steffensen K.R., Leers J., and Rafter J.J. Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands of PPAR gamma. Carcinogenesis 24 (2003) 1717-1722
41. Biasi F., Tessitore L., Zanetti D., Cutrin J.C., Zingaro B., Chiarpotto E., Zarkovic N., Serviddio G., and Poli G. Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumor progression. Gut 50 (2002) 361-367
42. Barrera G., Muraca R., Pizzimenti S., Serra A., Rosso C., and Saglio G. Inhibition of c-myc expression induced by 4-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. Biochem. Biophys. Res. Commun. 203 (1994) 553-561
43. Seoane J., Le H.V., and Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419 (2002) 729-734
44. Akasaki Y., Black K.L., and Yu J.S. Dendritic cell-based immunotherapy for malignant gliomas. Expert Rev. Neurother. 5 (2005) 497-508
45. Tsuchiya T., Shimizu H., Shimomura K., and Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am. J. Nephrol. 23 (2003) 222-228
46. Pizzimenti S., Laurora S., Briatore F., Ferretti C., Dianzani M.U., and Barrera G. Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic. Biol. Med. 32 (2002) 233-245
47. Barrera G., Pizzimenti S., Laurora S., Moroni E., Giglioni B., and Dianzani M.U. 4-Hydroxynonenal affects pRb/E2F pathway in HL-60 human leukemic cells. Biochem. Biophys. Res. Commun. 295 (2002) 267-275